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Abstract: EGFR amplification (EGFRamp), the combination of gain of chromosome 7 and loss of chro-
mosome 10 (7+/10-), and TERT promoter mutation (pTERTmut) are alterations frequently observed
in adult IDH-wild-type (IDHwt) glioblastoma (GBM). In the absence of endothelial proliferation and/or
necrosis, these alterations currently are considered to serve as a surrogate for upgrading IDHwt diffuse or
anaplastic astrocytoma to GBM. Here, we set out to determine the distribution of EGFRamp, 7+/10-,
and pTERTmut by analyzing high-resolution copy-number profiles and next-generation sequencing data
of primary brain tumors. In addition, we addressed the question whether combinations of partial gains
on chromosome 7 and partial losses on chromosome 10 exhibited a diagnostic and prognostic value similar
to that of complete 7+/10-. Several such combinations proved relevant and were combined as the 7/10
signature. Our results demonstrate that EGFRamp and the 7/10 signature are closely associated with
IDHwt GBM. In contrast, pTERTmut is less specific for IDHwt GBM. We conclude that, in the absence
of endothelial proliferation and/or necrosis, the detection of EGFRamp is a very strong surrogate marker
for the diagnosis of GBM in IDHwt diffuse astrocytic tumors. The 7/10 signature is also a strong sur-
rogate marker. However, care should be taken to exclude pleomorphic xanthoastrocytoma. pTERTmut
is less restricted to this entity and needs companion analysis by other molecular markers to serve as a
surrogate for diagnosing IDHwt GBM. A combination of any two of EGFRamp, the 7/10 signature and
pTERTmut, is highly specific for IDHwt GBM and the combination of all three alterations is frequent
and exclusively seen in IDHwt GBM.
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EGFR amplification (EGFRamp), the combination of gain of chromosome 7 and loss of chromosome 
10 (7+/10-) and TERT promoter mutations (pTERTmut) are alterations frequently observed in 
glioblastoma (GBM). In absence of endothelial proliferations and/or necrosis, these alterations 
currently are considered to serve as a surrogate for upgrading IDH wildtype (IDHwt) astrocytoma to 
GBM. Here we set out to determine the distribution of EGFRamp, 7+/10- and pTERTmut by analyzing 
intracranial tumors with high resolution copy number profiles (CNP) and sequencing data available. In 
addition, we addressed the question whether combinations of partial gains on 7 and losses on 10 
exhibited a diagnostic and prognostic value similar to that of complete 7+/10-. Several such 
combinations proved relevant and were combined and designated 7/10 signature. Our results 
demonstrate that EGFRamp and 7/10 are closely associated with GBM. In contrast, pTERTmut is less 
specific for GBM. We conclude that in the absence of endothelial proliferations and/or necrosis the 
detection of EGFRamp is a very strong surrogate marker for the diagnosis of GBM in diffuse astrocytic 
tumors. The 7/10 signature is also a strong surrogate marker. However, care should be taken to 
exclude pleomorphic xanthoastrocytoma. pTERTmut is less restricted to this entity and needs 
companion analysis by other molecular markers in order to serve as a surrogate for diagnosing GBM. 
A combination of any two of EGFRamp, 7/10 and pTERTmut is highly specific for GBM and the 












The so called IDH wildtype (IDHwt) astrocytoma comprises different tumors with the majority exhibiting 
molecular lesions and survival characteristics of glioblastoma (GBM). A pressing question is whether 
EGFR amplification, the presence of a combined gain on chromosome 7 and loss on chromosome 10 
and TERT promoter mutation can serve as surrogate marker for upgrading IDHwt astrocytoma, by 
definition lacking necrosis, to glioblastoma. 
The combination of gains on chromosome 7 and losses on chromosome 10 are characteristic 
molecular alterations in glioblastoma (GBM). Recent studies have demonstrated that astrocytic tumors 
not fulfilling the morphological criteria for GBM but exhibiting typical molecular features of GBM exhibit 
a clinical course similar to that of morphologically unequivocal GBM [5,11,24,30,31]. Therefore, the 
presence of the combination of 7gain and 10 loss is considered as molecular marker for GBM. Little is 
known about the relevance of assessing individual arms of chromosomes 7 and 10, i.e. does gain of 
either arm of 7 and loss of either arm of 10 suffice or is gain of both arms on 7 and loss of both arms 
on 10 required. Gain of chromosome 7 and loss of chromosome 10 in GBM haves been initially 
detected by cytogenetic analyses [25] [4]. The typical constellation found in GBM cell lines was trisomy 
of chromosomes 7 and monosomy of chromosome 10 most likely as a result of error in mitotic 
disjunction.  
EGFR amplification (EGFRamp) in GBM has been initially observed by molecular and cytogenetic 
analyses [18,33] [3,9]. Roughly half of the GBM exhibit a strong amplification of this gene mostly due 
to the presence of numerous double minutes, the extra chromosomal elements containing additional 
EGFR copies [28]. 
Telomerase reverse transcriptase (TERT) encodes the catalytic subunit of the telomerase complex. 
TERT promoter mutation (pTERTmut) initially has been detected in melanoma [12,13]. Subsequent 
investigations also revealed high frequencies of pTERTmut in GBM and in oligodendroglioma. 
[1,14,15,19,21,32],. and their potential use for subgrouping of glioma and in a diagnostic setting 
[2,7,8,22]. 
Recent technology development allows generating high resolution copy number profiles (CNP) of the 
human chromosomes in tumor tissue based on next generation sequencing or array data. We set out 
to address the distribution of EGFRamp, 7+/10- and pTERTmut in human brain tumors based on CNP, 
generated from DNA methylation array data sets and from next generation sequencing data. 






Material and Methods 
 
Patient cohorts 
The present analyses are based on data from three cohorts available for analysis at the Department. 
of Neuropathology of the University Heidelberg. From all patients in the three cohorts 450K/850K 
methylation array data are available. All patients have received a methylation based diagnosis as 
previously described [6].  
Cohort 1 contains 2.417 patients for whom next generation panel sequencing with a panel including 
the TERT gene and its promoter has been performed. Cohort 1 was employed for determining the 
distribution of pTERTmut, EGFRamp and 7+/10- in human brain tumors. Only one tumor per patient 
was included in cohort 1. Table 1 lists all tumors included in cohort 1 sorted by methylation based 
diagnosis. 
Cohort 2 including 10.826 brain tumor patients with have been analyzed using the Illumina 450K or 
850K platforms is the basis of the distribution of EGFRamp and 7+/10- in human brain tumors. Only 
one tumor per patient was included in cohort 2. Supplementary table 1 lists all tumors included in 
cohort 2 sorted by methylation based diagnosis [6] and respective number of patients. Cohort 2 
encompasses all patients from cohort 1. Details on methylation classes can be obtained from 
www.molecularneuropathology.org. 
Cohort 3 contains 939 patients from cohort 2 with survival data available. In contrast to cohorts 1 and 
2 the histological diagnosis according to WHO 2016 [20] including the diagnosis of IDHwt astrocytoma 
was basis for survival analysis. Cohort 3 does not include any patients diagnosed as glioblastoma. 
There is a bias in cohort 3 because survival data have been acquired for specific tumor entities in 
previous studies.  
 
Generation and scoring of CNPs and mutations 
Methylation data were generated using the Illumina 450K or 850K/EPIC platforms as previously 
described [6].The copy number variation plots were generated from the same raw data using the 
‘conumee’ R package in Bioconductor (http://www.bioconductor.org packages/release/bioc/html / 
conumee.html). Figure 1 shows representative CNPs. Automated assessment of copy-number 
changes was performed using the results from conumee after additional baseline correction. 
EGFRamp was called amplified if the respective probes exhibited an intensity higher than 0.6 on a 
log2-scale. 
Panel sequencing was performed a previously reported [26]. pTERTmut was scored if 10 or more 
reads were detected with a minimum of 10% of the reads showing either of the two TERT promoter 
mutations mutation.     
 
Statistics 
All patient sets were retrospectively compiled. The size of the respective sets was determined by 
availability of data and not by a power calculation. OS times were analyzed by the Kaplan-Meier 
method and compared with a log-rank test. P values less than 0.05 were considered significant. 
Software R version 3.4 and packages survival and party were employed for analysis 
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Results and Discussion 
 
Rationale and procedure 
We aimed at contributing to three questions: First, what is the incidence of combined 7/10 alterations, 
EGFRamp and pTERTmut in human brain tumors. Second, are these three alterations suitable 
surrogate markers for diagnosing GBM in the absence of necrosis and microvascular proliferation? 
and third, which variants of 7/10 alterations might be employed. The first two questions have been 
addressed by analyzing a series of 2,417 tumors (cohort 1) with both TERT promoter status and 
complete copy number profiles being available (table 1). Question three was addressed by analyzing 
an extended set of 10,826 patients (cohort 2) with complete copy number profiles available 
(supplementary table 1) and analyzing a subset thereof including 939 (cohort 3) patients with overall 
survival data available.  
For all series, both, a classical histopathological and a methylation based diagnosis was available. 
Current WHO GBM includes the H3-G34mutant GBM, while the H3-K27 GBM and the IDH mutant 
(IDHmut) GBM have been separated from the group of IDHwt GBM. For all questions addressing 
association of the markers interrogated with survival, we adhered to the current WHO definition of 
GBM (all analyses involving cohort 3). For determination of frequencies we used the methylation 
based diagnosis as this is highly standardized and, therefore, more suitable for this type of question. 
 
Defining 7/10 status 
An open question is whether 7+/10- is prognostically relevant only if both arms each chromosome are 
affected or if losses of only one arm per chromosome suffice. Further, how much of each 
chromosomal arm needs to be affected to score either a gain or a loss?. This question is of special 
interest in light of many data being FISH analysis based and, therefore, not providing representative 
information at all. Our approach is array platform based thereby covering the entire chromosomal 
arms. We selected two different thresholds with one being 50% and the other 80% of chromosomal 
representation being gained or lost for calling the respective alteration in cohort 1. Supplementary 
table 1 provides an overview of 7+ and 10- combinations using both thresholds. In the predominant 
GBM subgroup characterized by gain of entire 7 and loss of entire 10, 1185 patients (75% of all GBM) 
scored positive with the 80% and 1265 patients (81% of all GBM) with the 50% threshold 
(supplementary table 1). We therefore went on using the 50% threshold for all subsequent analyses. 
Of 9 possible combinations exhibiting both, gain of at least one arm on 7 and loss of at least one arm 
on 10, 7+/10- represents the most frequent (1265/1598; 79%) constellation followed by 7+/10q- 
(87/1598; 5%), by 7p+/10- (74/1598; 5%) and by 7q+/10- (70/1598; 4%) (supplementary table1 ).  
Next we analyzed which variants of gains and losses were associated with unfavorable clinical 
outcome. To this end we analyzed the respective combinations in patients from cohort 3.  
Of the nine possibilities for 7gain and 10loss combinations we encountered 7+/10‐ (n=97), 7q+/10‐ 
(n=12), 7+/10q‐ (n=9), 7q+/10q- (n=7), 7p+/10‐ (n=3), both 7+/10p‐ and 7q+/10p‐ (n=1), and both 
7p+/10p and 7p+/10q‐ (n=0) in patients from cohort 3. Survival analysis was performed of patients 
exhibiting the combinations 7+/10‐ (n=97), 7q+/10‐ (n=12), 7+/10q‐ (n=9), 7q+/10q‐ (n=7) and 
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7p+/10‐ (n=3). Three combinations, 7+/10‐ , 7q+/10‐ , 7+/10q‐ associated with poor survival similar to 
that of patients with GBM (figure 2a). We therefore defined all patients with 7+/10-, 7+/10q- and 
7q+/10- as carrying the prognostic 7/10 signature. Noteworthy, methylation based classification 
identified a substantial number of patients in cohort 3 without a 7/10 signature but with typical survival 
characteristics of GBM (figure 2b)demonstrating the power of this method. 
 
Distribution of EGFRamp, 7/10 signature and TERT in human brain tumors 
Comparison of the distribution of all three parameters was performed using cohort 2 although for the 
distribution of EGFRamp and 7/10 signature a higher resolution can be obtained from cohort 1. 
Frequent pTERTmut was observed in 363/544 (67%) GBM, in 95/120 (79%) oligodendroglioma, in 
12/17 (71%) melanoma, in 19/42 (45%) medulloblastoma methylation subclass SHH A and in 7/34 
(21%) pleomorphic xanthoastrocytoma (PXA). Numbers for pTERTmut in entities with low mutation 
frequencies or entities with only few tumors analyzed are given in the table 1. Of the three parameters, 
TERT exhibited highest sensitivity (67%) but lowest specificity (89%) for glioblastoma (table 2). 
The 7/10 signature was more specific for GBM being seen in 323/544 (59%) GBM, in 9/140 (6%) high 
grade IDHmut astrocytoma including IDHmut GBM and in 5/54 (9%) medulloblastoma of methylation 
subgroup 4 (table 1). Sensitivity was 59% and specificity was 98% (table 2). 
EGFRamp was observed in 196/544 (36%) GBM showing lowest sensitivity (36%) but highest 
specificity (100%) for GBM (table 2). 
On the entire scale pTERTmut (562/2417) is more frequent than EGFRamp (199/2417) or 7/10 
(361/2417). The combinations of pTERTmut – EGFRamp (28 cases), pTERTmut – 7/10 (146 cases) 
and EGFRamp – 7/10 (30 cases) were strongly associated with GBM and the triple combination of 
pTERTmut – 7+/10- - EGFRamp (124 cases) was exclusively seen in GBM (table 1).The sensitivity of 
any combination of double or triple positives was 58% and the specificity was 99% (table 2). 
 
Distribution of EGFRamp, 7/10 signature and pTERTmut in GBM methylation classes 
Subdivision of IDHwt GBM by methylation based classification results in 7 subgroups. These 
subgroups exhibit striking differences in the frequencies of the tree parameters interrogated. Tumors 
of the methylation class glioblastoma, IDHwt, H3.3 G34 mutant (n=17) did not exhibit pTERTmut or 
EGFRamp. The 7/10 signature was observed only in four H3.3 G34 mutant GBM . This finding is quite 
similar to that in H3.3 K27 mutant GBM and arguing for separating the H3.3 G34 mutant GBM from the 
IDHwt GBM, too. Tumors of the methylation class glioblastoma, IDHwt, subclass MYCN (n=22) 
exhibited pTERTmut and EGFRamp in less than quarter of all cases and the 7/10 signature only in a 
single tumor. Methylation class glioblastoma, IDHwt, subclass RTK I (n=71) presented with pTERTmut 
in 55 cases (77%), 18 (25%) times EGFRamp and 46 (65%) times the 7/10 signature. Methylation 
class glioblastoma, IDHwt, subclass RTK II (n=203) constituting the most frequent GBM subgroup 
presented with pTERTmut in 166 cases (83%), 128 (63%) times EGFRamp and 160 (79%) times the 
7/10 signature. The methylation class glioblastoma, IDHwt, subclass RTK III (n=23) predominantly 
encountered in young patients exhibited 11 times (48%) pTERTmut, 8 times (35%) EGFRamp and 3 
times (13%) 7/10. The methylation class glioblastoma, IDHwt, subclass mesenchymal (n=157) is 
frequent and presented with 123 (78%) pTERTmut, 37 (24%) EGFRamp and 109 (69%) 7/10 
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signatures. And finally tumors falling into the methylation class glioblastoma, IDHwt, subclass midline 
(n=51) which is a yet poorly characterized group of tumors with morphology and survival 
characteristics comparable to that of GBM [24] exhibited pTERTmut in 4 (8%) and EGFRamp or a 
7/10 signature in neither cases. 
Clearly as morphological GBM comprises all these methylation subgroups, the sensitivity of 
EGFRamp, 7/10 signature and pTERTmut based grading is compromised by the low or absent 
prevalence in some of these subgroups. 
 
Single use of one of the three parameters EGFRamp, 7/10 signature and pTERTmut 
A single molecular marker for diagnosing GBM in absence of necrosis would be a major contribution to 
daily routine diagnostics. While EGFRamp, pTERTmut or 7/10 signature are very good candidates, 
single use is not warranted. pTERTmut obviously needs accompanying analysis of IDH1 and IDH2 in 
order to exclude oligodendroglioma and astrocytoma. Also the rare adult medulloblastoma [23] and 
anaplastic meningioma [10,27] as well as SFT/Hemangiopericytoma frequently carry pTERTmut and 
need to be distinguished by appropriate testing. The presence of pTERTmut in PXA [16] should be 
addressed by testing for the BRAFV600E mutation typical for the latter [29]. However, an overlap with 
the rare epithelioid glioblastoma cannot be ruled out [17]. EGFRamp has highest specificity and IDH 
testing can separate the rare occurrences in IDH mutant glioma. The 7/10 signature also needs 
additional testing for IDH to separate for anaplastic diffuse glioma and for BRAF for its occasional 
occurrence in PXA (table 1). 
 
Conclusions 
Our data supports the single use of the molecular genetic markers EGFRamp, pTERTmut or 7/10 
signature as strong markers for the reclassification of IDHwt astrocytoma to GBM pending additional 
molecular tests. The combination of a positive finding for any two of the three parameters is highly 
specific for and the combination of all three parameters is exclusively seen in GBM.  
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Classifier prediction, EGFR, 7/10 and TERT status in cohort 1. Full text for abbreviated methylation 
classes is provided in supplementary table 1. A characterization of methylation classes by Classifier 
prediction can be obtained from www.molecularneuropathology.org. 
 
Table 2 
Sensitivity and specificity of pTERTmut, EGFRamp and 7/10 signature as single parameters and in 
combination for 544 GBM in a series of 2417 brain tumors.  
 
Figure 1 
Representative CNP-plots: a) GBM with 7+/10- and EGFRamp; b) GBM with 7+/10q-; c) PXA with 
7+/10- 
 
Figure 2.  
a) OS in 939 patients (cohort 3) which have been diagnosed as IDHwt glioma, excluding glioblastoma, 
stratified for different combinations of alterations of chromosomes 7 and 10. Of all possible 
combinations with losses on chromosomes 7 and 10, only 7+/10-, 7+/10q-,7p+10-, 7q+/10q- and 
7q+/10- were represented more than 3 times. Survival of glioma patients with 7+/10-, 7+/10q- and 
7q+/10- was significantly worse than that of patients without these alterations. 
b) OS in167 patients from cohort 3 which in addition have received the classifier diagnosis GBM. 
Methylation based classification identifies 52 additional patients without a 7/10 signature. Black graph 
is a reference series of additional 261 patients diagnosed as GBM by both, histology and methylation 
based classification. 
 
Supplementary table 1 
Distribution of EGFRamp and status of chromosomes 7 and 10 in 10.826 tumors. Chromosome 7 and 
10 status is given for two different thresholds requiring loss >50% or >80% of the respective arms. 

































































































Methylation class n n n n triple single single single double double double triple 
abbreviation total TERT EGFR 7/10 wt 7/10 EGFR TERT 7/10 + EGFR 7/10 + TERT EGFR + TERT  7/10 + EGFR + TERT 
PXA 34 7 0 2 26 1 0 6 0 1 0 0 
EFT_CIC 3 0 0 0 3 0 0 0 0 0 0 0 
HGNET_BCOR 9 0 0 0 9 0 0 0 0 0 0 0 
HGNET_MN1 6 0 0 0 6 0 0 0 0 0 0 0 
CNS_NB_FOXR2 1 0 0 0 1 0 0 0 0 0 0 0 
EWS 5 1 0 0 4 0 0 1 0 0 0 0 
O_IDH 120 95 0 1 25 0 0 94 0 1 0 0 
A_IDH 154 5 0 1 148 1 0 5 0 0 0 0 
A_IDH_HG 140 11 1 9 121 7 1 9 0 2 0 0 
ANA_PA 75 2 0 1 72 1 0 2 0 0 0 0 
ATRT_MYC 4 0 0 0 4 0 0 0 0 0 0 0 
ATRT_SHH 7 0 0 0 7 0 0 0 0 0 0 0 
ATRT_TYR 6 0 0 0 6 0 0 0 0 0 0 0 
CN 18 0 0 0 18 0 0 0 0 0 0 0 
LIPN 2 0 0 0 2 0 0 0 0 0 0 0 
CHGL 1 0 0 0 1 0 0 0 0 0 0 0 
CHORDM 4 1 1 2 2 0 0 0 1 1 0 0 
CPH_ADM 2 0 0 0 2 0 0 0 0 0 0 0 
CPH_PAP 4 0 0 0 4 0 0 0 0 0 0 0 
DLGNT 9 0 0 0 9 0 0 0 0 0 0 0 
DMG_K27 63 0 0 0 63 0 0 0 0 0 0 0 
ETMR 25 0 0 0 25 0 0 0 0 0 0 0 
EPN_RELA 14 0 0 0 14 0 0 0 0 0 0 0 
EPN_YAP 1 0 0 0 1 0 0 0 0 0 0 0 
EPN_MPE 15 0 0 1 14 1 0 0 0 0 0 0 
EPN_PF_A 34 0 0 2 32 2 0 0 0 0 0 0 
EPN_PF_B 6 1 0 0 5 0 0 1 0 0 0 0 
EPN_SPINE 4 0 0 0 4 0 0 0 0 0 0 0 
ENB_A 3 0 0 1 2 1 0 0 0 0 0 0 
ENB_B 2 0 0 0 2 0 0 0 0 0 0 0 
GBM_G34 17 0 0 4 13 4 0 0 0 0 0 0 
GBM_MYCN 22 4 5 1 14 0 4 2 0 1 1 0 
GBM_RTK_I 71 55 18 46 4 8 2 13 2 28 6 8 
GBM_RTK_II 203 166 128 160 6 7 4 21 20 41 12 92 
GBM_RTK_III 23 11 8 3 7 0 4 6 1 2 3 0 
GBM_MES 157 123 37 109 12 15 1 29 6 64 6 24 
GBM_MID 51 4 0 0 47 0 0 4 0 0 0 0 
HMB 4 0 0 0 4 0 0 0 0 0 0 0 
IHG 7 1 0 0 6 0 0 1 0 0 0 0 
LGG_MYB 14 0 0 0 14 0 0 0 0 0 0 0 
LGG_DIG_DIA 3 0 0 0 3 0 0 0 0 0 0 0 
LGG_DNT 19 0 0 0 19 0 0 0 0 0 0 0 
LGG_GG 12 3 0 2 9 0 0 1 0 2 0 0 
LGG_RGNT 8 0 0 0 8 0 0 0 0 0 0 0 
LGG_PA_GG_ST 30 1 0 1 29 0 0 0 0 1 0 0 
LGG_PA_MID 34 0 0 0 34 0 0 0 0 0 0 0 
LGG_PA_PF 78 0 0 0 78 0 0 0 0 0 0 0 
LGG_SEGA 13 0 0 0 13 0 0 0 0 0 0 0 
LYMPHO 13 0 0 0 13 0 0 0 0 0 0 0 
MB_WNT 34 2 0 0 32 0 0 2 0 0 0 0 
MB_SHH_CHL_AD 42 19 0 0 23 0 0 19 0 0 0 0 
MB_SHH_INF 47 1 0 0 46 0 0 1 0 0 0 0 
MB_G3 33 0 0 1 32 1 0 0 0 0 0 0 
MB_G4 54 4 0 5 45 5 0 4 0 0 0 0 
MELCYT 17 0 0 0 17 0 0 0 0 0 0 0 
MELAN 17 12 0 1 5 0 0 11 0 1 0 0 
SCHW_MEL 8 1 0 1 6 1 0 1 0 0 0 0 
MNG 476 22 0 2 453 1 0 21 0 1 0 0 
PTPR_A 4 0 0 0 4 0 0 0 0 0 0 0 
PTPR_B 14 0 0 0 14 0 0 0 0 0 0 0 
PGG_nC 8 0 0 0 8 0 0 0 0 0 0 0 
PIN_T_PPT 12 0 0 0 12 0 0 0 0 0 0 0 
PIN_T_PB_A 3 0 0 1 2 1 0 0 0 0 0 0 
PIN_T_PB_B 7 0 0 1 6 1 0 0 0 0 0 0 
PITUI 5 2 0 0 3 0 0 2 0 0 0 0 
PITAD_STH_DNS_B 1 0 0 0 1 0 0 0 0 0 0 0 
PLEX_AD 5 0 0 1 4 1 0 0 0 0 0 0 
PLEX_PED_A 6 0 0 2 4 2 0 0 0 0 0 0 
PLEX_PED_B 28 3 1 0 24 0 1 3 0 0 0 0 
SCHW 18 0 0 0 18 0 0 0 0 0 0 0 
SFT_HMPC 16 4 0 0 12 0 0 4 0 0 0 0 
SUBEPN_PF 2 1 0 0 1 0 0 1 0 0 0 0 
SUBEPN_SPINE 4 0 0 0 4 0 0 0 0 0 0 0 
SUBEPN_ST 6 0 0 0 6 0 0 0 0 0 0 0 






n n n n double double double triple any double 
total TERT EGFR  7/10  7/10 + EGFR 7/10 + TERT EGFR + TERT 7/10 + EGFR + TERT or triple 
true positive 363 196 323 29 136 28 124 317 
true negative 1674 1870 1835 1872 1863 1873 1873 1862 
false positive 199 3 38 1 10 0 0 11 
false negative 181 348 221 515 408 516 420 227 
sensitivity 66,7% 36,0% 59,4% 5,3% 25,0% 5,1% 22,8% 58,3% 























Methylation class atypical teratoid/rhabdoid tumor, subclass MYC
8
Methylation class IDH glioma, subclass astrocytoma
9
Methylation class IDH glioma, subclass high grade astrocytoma
16




Methylation class central neurocytoma
5
Methylation class CNS neuroblastoma with FOXR2 activation
12
Methylation class atypical teratoid/rhabdoid tumor, subclass SHH
13
Methylation class atypical teratoid/rhabdoid tumor, subclass TYR
10
Methylation class anaplastic pilocytic astrocytoma
18
Methylation class craniopharyngioma, adamantinomatous
19
Methylation class craniopharyngioma, papillary
20
Methylation class diffuse leptomeningeal glioneuronal tumor
21
Methylation class diffuse midline glioma H3 K27M mutant
2
Methylation class CNS Ewing sarcoma family tumor with CIC alteration
23
Methylation class ependymoma, RELA fusion
24
Methylation class ependymoma, YAP fusion
22
Methylation class embryonal tumor with multilayered rosettes
6
Methylation class Ewing sarcoma
3
Methylation class CNS high grade neuroepithelial tumor with BCOR alteration
4
Methylation class CNS high grade neuroepithelial tumor with MN1 alteration
15
Methylation class cerebellar liponeurocytoma
7
Methylation class IDH glioma, subclass 1p/19q codeleted oligodendroglioma
1
Methylation class (anaplastic) pleomorphic xanthoastrocytoma
29
Methylation class esthesioneuroblastoma, subclass A
27
Methylation class ependymoma, posterior fossa group B
28
Methylation class ependymoma, spinal
31
Methylation class glioblastoma, IDH wildtype, H3.3 G34 mutant
30
Methylation class esthesioneuroblastoma, subclass B
25
Methylation class ependymoma, myxopapillary
26
Methylation class ependymoma, posterior fossa group A
36
Methylation class glioblastoma, IDH wildtype, subclass mesenchymal
37
Methylation class glioblastoma, IDH wildtype, subclass midline
32
Methylation class glioblastoma, IDH wildtype, subclass MYCN
33
Methylation class glioblastoma, IDH wildtype, subclass RTK I
34
Methylation class glioblastoma, IDH wildtype, subclass RTK II
35
Methylation class glioblastoma, IDH wildtype, subclass RTK III
40





Methylation class infantile hemispheric glioma
ethylation class low grade glioma, desmoplastic infantile astrocytoma / ganglioglio
46
Methylation class low grade glioma, subclass midline pilocytic astrocytoma
43
Methylation class low grade glioma, ganglioglioma
42
Methylation class low grade glioma, dysembryoplastic neuroepithelial tumor
48
Methylation class low grade glioma, subependymal giant cell astrocytoma
47
Methylation class low grade glioma, subclass posterior fossa pilocytic astrocytoma
44
Methylation class low grade glioma, rosette forming glioneuronal tumor
45




Methylation class medulloblastoma, subclass group 3
50
Methylation class medulloblastoma, WNT
51
SHH_Methylation class medulloblastoma, subclass SHH A (children and adultCH
52








Methylation class medulloblastoma, subclass group 4
61
Methylation class paraganglioma, spinal non-CIMP
63
Methylation class pineoblastoma group A / intracranial retinoblastoma
64
Methylation class pineoblastoma group B
62
Methylation class pineal parenchymal tumor
Methylation class pituitary adenoma, TSH
66
Methylation class pituitary adenoma, ACTH
67
Methylation class pituitary adenoma, FSH/LH
65




PITAD_Methylation class pituitary adenoma, prolactinPRL
68
Methylation class pituitary adenoma, STH densely granulated, group A
60
Methylation class papillary tumor of the pineal region group B
74
Methylation class plexus tumor, subclass adult
69
Methylation class pituitary adenoma, STH densely granulated, group B
70
Methylation class pituitary adenoma, STH sparsely granulated
71
57
Methylation class melanotic schwannoma
59
Methylation class papillary tumor of the pineal region group A
75




Methylation class plexus tumor, subclass pediatric B
79
Methylation class solitary fibrous tumor / hemangiopericytoma
82
Methylation class subependymoma, supratentorial
80
Methylation class subependymoma, posterior fossa
81
Methylation class subependymoma, spinal
abbrev. n EGFRamp EGFRwt EGFRamp % threshold %
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
1.2
0.0
0.0
0.0
1.4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.2
0.0
1.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
106
161
15
109
61
30
16
17
81
41
49
29
199
85
62
58
56
121
528
640
351
112
ATRT_MYC 0 81
A_IDH 0 640
A_IDH_HG 4 347
112
81
CHGL 0 17
CHORDM 1 80
CN 0 30
CNS_NB_FOXR2 0 56
ATRT_SHH 0 109
ATRT_TYR 0 61
ANA_PA 0
CPH_ADM 0 41
CPH_PAP 0 49
DLGNT 0 29
DMG_K27 4 288292
EFT_CIC 0 85
EPN_RELA 0 161
EPN_YAP 0 15
ETMR 0 106
EWS 0 121
HGNET_BCOR 0 62
HGNET_MN1 0 58
LIPN 0 16
O_IDH 1 527
PXA 0 199
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
0.0
0.0
0.0
0.0
0.0
0.0
31.0
27.9
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
3.8
25.5
20.9
68.6
1.3
279
29
39
105
47
350
873
42
705
125
57
37
76
367
95
59
23
22
ENB_A 0 23
59
EPN_PF_A 0 367
EPN_PF_B 0 95
EPN_SPINE 0
GBM_G34 4 101
ENB_B 0 22
EPN_MPE 1 75
GBM_MES 197 508
GBM_MID 0 125
GBM_MYCN 12 35
GBM_RTK_I 73 277
GBM_RTK_II 599 274
GBM_RTK_III 13 29
88
18
136
LGG_MYB 0 88
HMB 0 57
IHG 0 37
LGG_DIG_DIA 0 18
120
LGG_PA_MID 0 115
LGG_GG 0 7575
26
120
115
LGG_DNT 0 136
LGG_SEGA 0 29
LGG_PA_PF 0 279
LGG_RGNT 0 26
LGG_PA_GG_ST 0
LYMPHO 0 39
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
50
80
0.0
5.9
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.8
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
36
55
48
53
15
27
28
25
17
10
87
13
1058
11
32
24
37
24
43
125
253
142
257
513
56
MB_G3 0 257
MB_WNT 0 125
513
MB_SHH_CHL_AD 0 253
MB_SHH_INF 0 142
MNG 1 1057
MELAN 0 87
MELCYT 1 55
MB_G4 0
PGG_nC 0 24
PIN_T_PB_A 0 24
PIN_T_PB_B 0 43
PIN_T_PPT 0 37
PITAD_TSH 0
PITAD_ACTH 0 48
PITAD_FSH_LH 0 53
25
PITUI 0 55
PLASMA 0 10
PITAD_PRL 1 16
PITAD_STH_DNS_A
11
PTPR_B 0 32
PLEX_AD 0 36
0 15
PITAD_STH_DNS_B 0 27
PITAD_STH_SPA 0 28
SCHW_MEL 0 13
PTPR_A 0
50
80
50
80
50
80
50
80
50
80
50
80
50
80
0.0
0.0
3.1
2.3
0.6
0.0
1.9
32
307
155
37
54
19
25
PLEX_PED_A 1 31
SCHW 1 154
PLEX_PED_B 7 300
SFT_HMPC 0 37
SUBEPN_ST 0 25
SUBEPN_PF 1 53
SUBEPN_SPINE 0 19
7pwt_7qwt_10pwt_10qwt 7pwt_7qwt_10pwt_10qloss 7pwt_7qwt_10ploss_10qwt
90 6 5
93 4 5
71 1 3
72 1 3
57 1 0
57 1 0
44 2 0
44 2 0
39 10 0
45 4 1
96 3 3
96 3 3
460 4 2
481 1 2
416 22 2
490 8 2
133 79 4
205 38 7
70 7 14
79 4 13
76 0 3
77 0 2
98 2 0
98 2 0
57 0 0
57 0 0
30 0 0
30 0 0
14 1 0
14 1 0
17 0 0
17 0 0
27 0 1
27 2 1
36 0 1
36 0 1
40 1 2
40 1 2
18 0 0
18 0 0
180 40 3
199 27 4
76 0 6
78 0 6
128 1 2
128 1 2
15 0 0
15 0 0
23 0 0
23 0 0
317 10 4
319 8 4
6 0 2
6 0 2
28 0 1
28 0 1
2 0 0
2 0 0
2 0 0
2 0 0
36 21 3
57 5 4
11 6 0
15 4 0
4 4 0
4 5 1
6 3 2
9 3 2
13 4 0
15 3 1
39 7 5
42 7 5
68 9 4
81 6 3
56 0 0
56 0 0
32 0 1
32 0 1
87 0 1
87 0 1
15 0 2
15 0 2
120 0 0
120 0 0
53 3 1
55 1 1
24 0 0
25 0 0
84 0 1
85 0 0
106 0 1
107 0 0
244 1 1
245 1 1
29 0 0
29 0 0
27 0 1
30 0 0
103 3 3
105 1 3
184 39 1
200 25 1
106 9 2
108 7 2
76 21 1
100 7 1
248 13 6
270 3 7
53 2 0
53 2 0
27 4 5
30 5 6
8 0 0
8 0 0
828 44 18
841 37 17
1 0 0
2 0 0
1 0 0
1 0 0
24 0 0
24 0 0
29 0 1
29 0 1
19 1 0
20 0 0
16 1 0
18 0 0
50 1 0
51 0 0
32 0 0
32 0 0
51 1 0
52 0 0
3 0 0
3 0 0
21 3 0
22 2 0
28 0 0
28 0 0
9 1 0
9 1 0
1 1 0
1 1 0
6 0 0
6 0 0
1 0 0
1 0 0
18 0 0
18 0 0
172 16 18
177 14 19
146 0 2
147 0 1
37 0 0
37 0 0
50 1 1
51 0 1
18 0 1
18 0 1
25 0 0
25 0 0
7pwt_7qwt_10ploss_10qloss 7pwt_7qgain_10pwt_10qwt 7pwt_7qgain_10pwt_10qloss
32 2 0
31 3 0
3 1 0
4 1 0
1 0 0
1 0 0
10 0 0
10 0 0
2 0 0
1 0 0
11 0 0
11 0 0
12 23 0
12 7 0
0 131 5
0 80 1
32 33 16
31 20 5
6 5 0
6 3 0
1 0 0
1 0 0
5 0 0
5 0 0
0 0 0
0 0 0
0 0 0
0 0 0
1 0 0
1 0 0
0 0 0
0 0 0
19 1 1
18 1 0
0 0 0
0 0 0
3 0 0
3 0 0
2 4 0
2 4 0
26 6 3
25 6 3
7 0 0
7 0 0
16 0 0
16 0 0
0 0 0
0 0 0
17 0 0
17 0 0
7 1 0
7 1 0
18 0 0
18 0 0
5 0 0
5 0 0
9 0 0
9 0 0
16 0 0
16 0 0
4 5 1
2 5 0
9 3 2
9 4 0
39 0 0
42 2 0
82 0 2
98 1 2
6 0 0
5 0 0
108 6 3
114 7 2
19 5 0
17 3 0
1 0 0
1 0 0
2 0 0
2 0 0
0 0 0
0 0 0
1 0 0
1 0 0
3 1 0
3 1 0
0 1 0
0 1 0
0 1 0
0 0 0
2 1 0
2 1 0
0 0 0
0 0 0
1 1 0
1 2 0
0 0 0
0 0 0
2 3 0
1 2 0
9 1 0
9 1 0
14 4 1
12 5 1
13 0 0
13 0 0
38 10 13
38 14 2
15 24 3
16 17 0
0 0 0
0 0 0
12 2 2
13 2 2
1 0 0
1 0 0
103 20 3
102 18 2
6 0 0
6 0 0
30 0 0
30 0 0
0 0 0
0 0 0
4 0 0
4 0 0
1 0 0
1 0 0
3 2 1
4 1 1
1 1 0
1 1 0
10 0 0
10 0 0
0 0 0
0 0 0
1 0 0
1 0 0
0 0 0
0 0 0
0 0 0
0 0 0
4 0 0
4 0 0
0 0 0
0 0 0
1 0 0
1 0 0
2 1 0
2 1 0
2 0 0
2 0 0
44 2 0
44 2 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
7pwt_7qgain_10ploss_10qwt 7pwt_7qgain_10ploss_10qloss 7pgain_7qwt_10pwt_10qwt
1 3 3
0 3 4
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 2
0 0 2
1 0 2
1 0 1
1 0 8
1 0 6
1 5 5
0 2 5
0 1 2
0 0 2
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
1 0 1
1 0 2
0 0 0
0 0 1
0 0 1
0 0 2
0 0 0
0 0 0
0 0 10
0 0 8
0 0 3
0 0 2
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 1
0 0 1
0 0 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 3 4
0 3 4
1 0 2
0 0 3
0 8 2
0 9 2
1 35 0
0 53 1
1 0 2
0 0 3
3 24 8
1 32 9
0 0 6
0 0 7
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 2
0 0 2
0 0 0
0 0 0
0 0 2
0 0 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 1 1
0 1 1
0 0 1
0 0 1
1 3 3
1 4 3
1 3 7
0 2 8
0 0 0
0 0 0
3 4 4
1 2 4
0 1 0
0 1 0
0 3 2
0 3 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 1
0 0 0
0 0 0
0 1 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 1 1
0 1 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
1 2 6
0 2 7
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
7pgain_7qwt_10pwt_10qloss 7pgain_7qwt_10ploss_10qwt 7pgain_7qwt_10ploss_10qloss
0 0 1
0 0 1
0 1 1
0 1 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
6 0 0
3 0 0
0 1 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
1 0 0
1 0 0
0 0 0
0 0 0
1 0 0
1 0 0
0 0 0
0 0 0
2 2 0
1 1 0
0 2 0
0 2 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 1
0 0 1
0 0 1
2 0 1
2 0 3
0 0 3
0 0 3
2 1 12
3 0 18
3 0 30
1 0 35
0 0 1
0 0 1
1 1 25
1 1 32
3 1 2
0 0 2
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
2 0 0
0 0 0
0 1 1
0 1 1
0 0 0
0 0 0
1 1 0
1 1 0
0 0 0
0 0 0
0 0 2
0 0 2
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
1 0 0
1 0 0
0 0 0
0 0 0
5 0 7
4 0 4
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
7pgain_7qgain_10pwt_10qwt 7pgain_7qgain_10pwt_10qloss 7pgain_7qgain_10ploss_10qwt
38 0 2
37 0 3
2 0 1
2 0 0
2 0 1
2 0 1
1 0 0
1 0 0
4 1 0
5 0 0
5 0 1
5 0 1
22 1 0
21 1 0
53 2 0
52 0 0
25 10 1
30 3 1
5 0 0
4 0 0
1 0 0
1 0 0
2 0 0
2 0 0
4 0 0
4 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
10 1 0
10 0 0
3 0 1
2 0 1
1 0 0
0 0 0
5 0 0
5 0 0
16 1 0
15 0 0
11 1 0
10 1 0
10 0 2
11 0 1
0 0 0
0 0 0
30 0 0
30 0 0
23 2 0
23 2 0
60 0 3
60 0 3
23 0 0
23 0 0
2 1 0
2 1 0
1 0 0
1 0 0
11 11 0
14 5 1
7 1 0
6 1 0
36 28 4
37 25 4
35 29 11
45 23 8
5 2 1
7 0 0
43 16 8
43 15 10
7 0 0
5 0 0
0 0 0
0 0 0
2 0 0
2 0 0
0 0 0
0 0 0
0 0 0
0 0 0
10 0 0
10 0 0
15 0 0
15 0 0
1 0 0
1 0 0
28 0 0
28 0 0
8 0 0
8 0 0
29 0 0
28 0 0
0 0 0
0 0 0
6 0 0
6 0 0
5 0 0
5 0 0
7 1 0
7 0 0
10 1 0
11 0 0
60 10 3
66 4 2
127 18 6
134 8 6
1 0 0
1 0 0
13 4 2
13 3 1
3 0 0
3 0 0
33 1 0
33 1 0
3 0 0
2 0 0
1 0 0
1 0 0
0 0 0
0 0 0
2 0 0
2 0 0
2 1 0
2 1 0
13 1 0
14 0 0
2 0 0
2 0 0
4 0 0
4 0 0
1 0 0
1 0 0
9 0 0
9 0 0
1 0 0
1 0 0
0 0 0
0 0 0
9 0 0
9 0 0
14 0 1
15 0 0
3 0 0
3 0 0
21 0 0
21 0 0
7 0 0
7 0 0
23 1 2
24 1 1
7 0 0
7 0 0
0 0 0
0 0 0
2 0 0
2 0 0
0 0 0
0 0 0
0 0 0
0 0 0
7pgain_7qgain_10ploss_10qloss
16
15
1
1
0
0
1
1
0
0
0
0
1
1
0
0
1
1
1
1
0
0
2
2
0
0
0
0
0
0
0
0
18
18
0
0
0
0
0
0
3
3
0
0
2
2
0
0
4
4
2
2
6
6
2
2
8
8
2
2
3
0
2
2
210
198
634
592
7
7
408
384
1
1
0
0
0
0
0
0
0
0
0
0
2
2
0
0
2
2
0
0
0
0
0
0
0
0
1
1
0
0
0
0
16
15
40
40
0
0
3
3
0
0
1
1
1
1
0
0
0
0
0
0
0
0
5
5
0
0
1
1
0
0
2
2
0
0
0
0
2
2
0
0
0
0
10
10
5
5
8
8
0
0
0
0
0
0
0
0
0
0
0
